Dr. Rakesh Ranjan
Psychiatry (Psychiatry Physician)
801 E Washington St, Suite 150
Medina, OH 44256
Who else practices at this address →
Medina County is a federal mental health shortage area. About shortage areas
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
OH license 35-064379R
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Rakesh Ranjan M.d. and Assoc., Inc (20 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Testing for presence of drug, read by direct observation | 89 | 11 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 60 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 52 | 34 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ziprasidone Hcl Other prescribers in Medina, OH | 20 |
| Clonazepam Other prescribers in Medina, OH | 17 |
| Sertraline Hcl Other prescribers in Medina, OH | 17 |
| Donepezil Hcl Other prescribers in Medina, OH | 13 |
| Bupropion Xl (bupropion hcl) Other prescribers in Medina, OH | 11 |
| Mirtazapine Other prescribers in Medina, OH | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 172 payments worth $12,399 in total to this clinician.
| Teva Pharmaceuticals USA, Inc. | $10,221 |
|---|---|
| Otsuka America Pharmaceutical, Inc. | $682 |
| Vanda Pharmaceuticals Inc. | $371 |
| Alkermes, Inc. | $229 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $220 |
| AbbVie Inc. | $196 |
| E.r. Squibb & Sons, L.l.c. | $153 |
| Indivior Inc. | $76.54 |
| Compensation for services other than consulting (speaking, faculty) | $8,508 |
|---|---|
| Food and Beverage | $2,963 |
| Consulting Fee | $705 |
| Education | $223 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. May 29, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Teva Pharmaceuticals USA, Inc. Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Teva Pharmaceuticals USA, Inc. Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $2,008 |
| Teva Pharmaceuticals USA, Inc. Aug 25, 2025 | Consulting Fee AUSTEDO XR · Central Nervous System | $705 |
| Teva Pharmaceuticals USA, Inc. Sep 5, 2025 | Education in-kind | $111 |
| Teva Pharmaceuticals USA, Inc. Apr 7, 2025 | Education in-kind | $111 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $139,678 in research payments for these studies, mostly to the institutions running them.
- ITI-007-421
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - Safety and tolerability of open-labeled iloperidone in adolescents
Vanda Pharmaceuticals Inc. - ITI-007-601
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - RECOVER
Livanova USA, Inc. - ITI-007-321
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
E.r. Squibb & Sons, L.l.c. - An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Sumitomo Pharma America, Inc. · Completed · NCT05741528 - RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatme…
Livanova USA, Inc. - Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. · Completed · NCT03238326
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.